Study identifies different patient priorities when selecting biologics for PsAOctober 24, 2021Psoriatic Arthritis
PsA: Phase 3 confirms rapid and significant response of secukinumab on synovitisOctober 24, 2021Psoriatic Arthritis
Psoriasis patients initiating biologics more likely to develop PsAOctober 24, 2021Psoriatic Arthritis
Disease activity-guided dose optimization of TNF inhibitors safe and effective in PsAOctober 24, 2021Psoriatic Arthritis
Dermatology NewsBetter COVID-19 outcomes confirmed in TNF inhibitor usersOctober 22, 2021COVID-19 UpdatesPsoriatic ArthritisPsoriasis
Dermatology NewsFew JAK inhibitor users have diminished immune response to COVID-19 vaccinesOctober 18, 2021COVID-19 UpdatesPsoriatic Arthritis
Dermatology NewsAdalimumab biosimilar Cyltezo gets interchangeability designationOctober 18, 2021PediatricsPsoriatic Arthritis
Dermatology NewsStudy of biologics’ impact on psoriasis-to-PsA transition contradicts previous findingsOctober 13, 2021Psoriatic ArthritisPsoriasis
Dermatology NewsFirst-in-class TYK inhibitor shows durable effect for psoriasisOctober 1, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsAcceptance of biosimilars grows but greater use may hinge on switching, interchangeability studiesSeptember 30, 2021Psoriatic ArthritisPediatricsPsoriasis
Dermatology NewsMore severe psoriasis linked to an increased risk of PsASeptember 28, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsEuropean agency recommends two new adalimumab biosimilarsSeptember 20, 2021Psoriatic ArthritisPediatricsPsoriasis
Dermatology NewsMedicare patients’ cost burden for specialty psoriasis, PsA drugs remains highSeptember 15, 2021PsoriasisPsoriatic Arthritis
Dermatology NewsAsk about itch and joint pain in pediatric psoriasis patients, expert advisesSeptember 2, 2021PsoriasisPediatricsPsoriatic Arthritis
Dermatology NewsThree JAK inhibitors get boxed warnings, modified indicationsSeptember 2, 2021Psoriatic ArthritisPediatricsAtopic Dermatitis
